Drug intelligence / Profile preview

BC0002

Development stage: Preclinical
Lead developer: Protheragen
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

BC0002 is a dual-payload antibody-drug conjugate (ADC) targeting the human epidermal growth factor receptor 2 (HER2), currently in the discovery phase of development by Protheragen. The asset is designed to deliver two distinct cytotoxic agents to HER2-expressing tumor cells, a strategy intended to enhance therapeutic efficacy and mitigate potential drug resistance compared to single-payload ADCs. BC0002 is being explored for the treatment of various HER2-positive solid tumors.

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on BC0002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BC0002.

Explore the full profile